Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanreotide in Small Bowel Motility Disorders
NCT03012594Phase 2Completed
- Sponsor
- Northwell Health
- Start
- May 2017
- Primary completion
- Oct 2018
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lanreotide in small intestinal dysmotility (SID), sponsored by Northwell Health. Primary endpoint: Effect of Lanreotide on Gastrointestinal Motility as Measured by Smart Pill at 3 months. Started May 2017; status: completed.
02
Drugs
lanreotide
03
Conditions
small intestinal dysmotility (SID)
Beyond the preview
Go deeper on NCT03012594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03012594.